We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Biomarker-Based Blood Test Developed for Early Cancer Diagnosis

By LabMedica International staff writers
Posted on 20 Aug 2018
Print article
Image: A micrograph of the most common type of renal cell carcinoma (clear cell) on right of the image; non-tumor kidney is on the left of the image (Photo courtesy of Wikimedia Commons).
Image: A micrograph of the most common type of renal cell carcinoma (clear cell) on right of the image; non-tumor kidney is on the left of the image (Photo courtesy of Wikimedia Commons).
A blood test for early detection of kidney cancer is based on the KIM-1 (Kidney-injury-molecule-1) protein biomarker.

Renal cell carcinoma (RCC) has the potential for cure with surgery when diagnosed at an early stage. To this end, KIM-1 has been shown to be elevated in the plasma of RCC patients.

In the current study, investigators at Brigham and Women's Hospital (Boston, MA, USA) examined whether plasma KIM-1 could represent a means of detecting RCC prior to clinical diagnosis.

The investigators measured KIM-1 concentrations in samples from patients enrolled in the European Prospective Investigation into Cancer and nutrition (EPIC). KIM-1 levels from 190 participants who went on to develop RCC within the next five years were compared to those from 190 matched participants (same age, body mass index, smoking status, etc.) who remained healthy.

In samples with detectable levels of KIM-1, the average concentration was double in those who would develop kidney cancer. Furthermore, compared with a risk model including known risk factors of RCC (age, sex, country, body mass index, and tobacco smoking status), a risk model that additionally included KIM-1 substantially improved discrimination between cases and controls. In addition, high plasma KIM-1 concentrations were associated with poorer survival.

"Early detection of kidney cancer can be lifesaving. We can cure kidney cancer when we detect it at an early stage, but patients with advanced kidney cancer have a very high death rate," said contributing author Dr. Venkata Sabbisetti, a researcher in the renal division of Brigham and Women's Hospital. "However, kidney cancer is asymptomatic and many patients present with advanced kidney cancer at the time of diagnosis. Our results suggest that with further refinement, KIM-1 has the potential to identify patients with early, curable kidney cancer."

The KIM-1 study was published in the July 23, 2018, online edition of the journal Clinical Cancer Research.

Related Links:
Brigham and Women's Hospital

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.